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Accumulating evidence suggests that
inhibition of tumor angiogenesis is an
effective strategy to block the growth of
certain tumors. The vascular endothelial
growth factor (VEGF) family of angio-
genic factors has been shown to play an
important role in tumor angiogenesis.
VEGF, through interaction with its cog-
nate tyrosine-kinase receptor, VEGF-
receptor-2 (VEGF-R2, also known as
KDR, Flk-1), conveys signals that support
proliferation, survival, and motility of
endothelial cells (Figure 1). Anti-VEGF-
R2 agents, including small molecule tyro-
sine kinase inhibitors targeted at
VEGF-R2, are highly effective in blocking
tumor angiogenesis and growth in murine
tumor models. However, translation of
these strategies to a clinical setting has
proven difficult, in part due to toxicities,
particularly when these agents are used
in combination with chemotherapeutic
agents (Marx et al., 2002). Another
obstacle in the clinical application of
antiangiogenic factors is the delivery of
sufficient amounts of bioavailable anti-
VEGF-R2 agents selectively to the tumor
vasculature to faithfully block VEGF-R2
activity. In most cases, chronic long-term
delivery of high doses is necessary to
achieve a clinical response. One strategy
to circumvent the hurdles associated with
chronic therapy has been to take advan-
tage of inherent immune response to
selectively target tumor neovasculariza-
tion, thereby eliminating the need for
long-term expensive delivery of high
doses of potentially toxic agents.
Breaking immune tolerance against
angiogenic-associated molecules, includ-
ing VEGF-R2, which is upregulated in
proliferating tumor endothelial cells,
provides a novel strategy to block tumor
angiogenesis (Figure 1A). Tumor endo-
thelial cells are genetically stable and
readily accessible to the bloodstream;
therefore, breaking immune tolerance can
deliver cytotoxic T lymphocytes and anti-
bodies directly to the neoangiogenic
tumor VEGF-R2+ endothelial cells.
Several groups have succeeded in induc-
ing the immune response against VEGF-
R2 by breaking immune tolerance. In one
pioneer study, the mice were immunized
against VEGF-R2 by pulsing in vitro-gen-
erated dendritic cells with soluble VEGF-
R2 (Li et al., 2002). This immunization
strategy generated VEGF-R2-specific
neutralizing antibody and CD8+ cytotoxic
T cell responses (CTL), thereby breaking
tolerance to self-VEGF-R2 antigen.
Development of pulmonary metastasis
was strongly inhibited in mice challenged
with B16 melanoma or Lewis lung (LL)
carcinoma cells. Development of cytotoxic
CD8+ cells targeted at VEGF-R2 was
shown to effectively destroy tumor
endothelial cells (Figure 1B). Another
mechanism for the antiangiogenic effect
was mediated through the generation of
specific neutralizing monoclonal that
blocked the binding of VEGF to VEGF-R2,
thereby blocking tumor angiogenesis
(Figure 1C).
In a similar study reported by
Niethammer et al., an oral DNA vaccine
delivered by attenuated Salmonella
typhimurium genetically engineered to
express VEGF-R2 was used to break
immune tolerance to self-VEGF-R2 anti-
gen (Niethammer et al., 2002). This strat-
egy was highly effective in inhibiting tumor
growth in mice challenged with subcuta-
neous injection of B16 melanoma and LL
carcinoma. Oral DNA vaccination with
VEGF-R2 was also effective in diminish-
ing tumors in mice inoculated with CT-26
colon carcinoma with fully established
pulmonary metastasis. All such treated
mice survived and showed only a few
small lung metastatic foci, while all of the
unvaccinated control mice succumbed to
tumor metastasis. The mechanism for
inhibition of tumor angiogenesis was cell-
mediated immunity with cytotoxic CD8+
cells selectively targeting VEGF-R2+
tumor endothelium (Figure 1B).
Other immunogene therapy strate-
gies to target tumor angiogenesis have
used crossimmunization with xeno-
geneic endothelial cells as a vaccine to
induce endothelial-specific immune
responses against tumor vasculature
(Wei et al., 2000). In this model, the
immune response was directed toward
integrin αv and VEGF-R2, again under-
scoring the significance of VEGF-R2 in
regulating tumor angiogenesis. In
support of this approach, xenogenic
crossimmunization with αvβ3 integrin has
also been shown to inhibit tumor growth
in mice (Lou et al., 2002). Immunization
with liposomal basic-fibroblast growth
factor (FGF-2) peptide vaccine (Plum et
al., 2000) or VEGF DNA vaccine (Wei et
al., 2001) has also resulted in the gener-
ation of neutralizing antibodies, which
effectively blocked tumor angiogenesis.
Vaccination against calreticulin in con-
junction with a model viral tumor antigen
was used to generate both an antitumor
and an antiangiogenesis effect (Cheng
et al., 2001). Collectively, these studies
identify angiogenic factors and their
receptors as effective tumor-specific tar-
gets for immunogene therapy to block
tumor angiogenesis and growth.
But could these immunogene thera-
py strategies against tumor angiogene-
sis ever succeed in a clinical setting?
Although expression of VEGF-R2 during
embryonic development is absolutely
essential for angiogenesis and vasculo-
genesis, the exact functional role of
VEGF-R2 expression in adults is not fully
known. As upregulation of functional
VEGF-R2 also plays a critical role in reg-
ulating various postnatal physiological
processes, including wound healing and
fertility, acute or long-term inhibition of
VEGF-R2 might result in the generation
of life-threatening complications.
So what are the potential clinical tox-
icities that may be expected from
immunogene therapy against VEGF-R2?
Remarkably, only a modest delay in
wound healing was detected in mice vac-
cinated with oral VEGF-R2 DNA, while
fertility, neuromuscular function, and
hematopoietic reconstitution were pre-
served (Niethammer et al., 2002). In
contrast, mice vaccinated with VEGF-
R2-pulsed dendritic cells showed signifi-
cant impairment in fertility, while wound
healing and hematopoiesis remained
intact (Li et al., 2002). The differences in
the toxicity profile of these two approach-
es may be dependent on the affinity or
specificity of autoantibodies to epitopes
Vaccination against tumor neovascularization: Promise and reality
Immunization against angiogenic-associated antigens selectively expressed on tumor vasculature provides for a novel
strategy to block tumor growth.The feasibility of this approach has recently been borne out in several reports demonstrat-
ing that the protein or DNA of angiogenic molecules, such as VEGF-R2, can be used as vaccines to generate an effective
cytotoxic T cell and antibody response against tumor vessels, thereby blocking tumor growth and metastasis.
430 CANCER CELL : DECEMBER 2002
P R E V I E W S
of VEGF-R2. As signaling through
VEGF-R2 is modulated through collabo-
ration with other membrane-bound mole-
cules, such as neuropilins or integrins
(i.e., αvβ3), it is possible, then, that the
two different approaches block different
epitopes, thereby interfering with sepa-
rate physiological functions of VEGF-R2.
Understanding the exact mechanisms by
which immunogene therapy blocks tumor
angiogenesis is critical to obviate toxicity
to the normal vasculature.
One potential toxicity in humans that
is difficult to assess in animal models is
the duration of immune response that is
associated with immunogene therapy
models. In murine models described
above, immune response to VEGF-R2
persisted for several months (Li et al.,
2002; Niethammer et al., 2002).
Therefore, it is very difficult to predict
how long such an approach will confer
immunity against VEGF-R2 in humans.
Prolonged VEGF-R2 inhibition may also
contribute to long-term end-organ toxici-
ties, indicating that strategies to turn off
immune response to VEGF-R2 should
be implemented.
Despite these expected toxicities, the
aforementioned immunotherapy studies
have several advantages over conven-
tional tumor immunotherapy, where tumor
antigens are the main targets of cytotoxic
T cells. For example, tumor cells can
downregulate HLA class I antigen expres-
sion (Hicklin et al., 1999), whereby the
tumor cells become resistant to the
immune response. However, since
endothelial cells are genetically stable, it
is unlikely that immunotherapy will result
in the development of resistance or eva-
sion of immune response. Moreover,
antiangiogenic vaccines can theoretically
target different types of tumors, as long as
their growth is angiogenesis-dependent. It
is also possible to retarget the same
tumor with booster shots to reactivate the
cytotoxic response without generation of
resistance thereby, obviating the need for
long-term chronic and economically over-
bearing therapy. Finally, there is no doubt
that many other angiogenesis-associated
antigens besides VEGF-R2 are selective-
ly expressed or upregulated on human
tumor endothelial cells, each representing
a potential target for immunotherapy (St
Croix et al., 2000). As formation of tumor
vessels is governed by activation of
several angiogenic pathways, future
immunotherapy protocols targeting one
single angiogenic pathway may be inade-
quate to completely block tumor growth.
Immunogene therapy targeted at several
tumor-specific angiogenic epitopes may
be more effective to completely block
tumor angiogenesis and growth while
diminishing long-term toxicity to end-
organ vasculature.
Rigorous controlled clinical studies
are in order to assess the efficacy of
immunogene therapy against tumor
angiogenesis. In particular, preclinical
studies should focus on identifying
potential toxicities that may be associat-
ed with long-term immune-mediated
VEGF-R2 inhibition in human subjects.
For example, as angiogenesis plays a
critical role in arteriogenesis and collat-
eral vessel formation, chronic long-term
or even short-term inhibition of VEGF-R2
may result in major hemostatic complica-
tions after cardiac or cerebral vascular
ischemia. Moreover, since VEGF iso-
forms may serve functions to maintain
pulmonary and kidney function, chronic
VEGF-R2 inhibition may also be associ-
ated with pulmonary or renal complica-
Figure 1. Inhibition of tumor angiogenesis by
immunogene therapy against VEGF:VEGF-
R2 signaling pathway
Differential expression of certain angiogenic-
associated molecules, such as VEGF-R2, pro-
vides ideal readily accessible antigenic
targets to activate immune response against
tumor endothelial cells. 
A: Although VEGF-R2 is expressed in certain
normal adult vasculature, its expression is suf-
ficiently upregulated in tumor vasculature to
allow for generation of cell-mediated immu-
nity against tumor endothelial cells. 
B: Immunogene therapy against VEGF-R2
takes advantage of the capacity of
endothelial cells to express MHC class I anti-
gen. Tumor endothelial cells present
processed VEGF-R2 peptide fragments in
conjunction with the MHC class I to the T cell
receptor (TCR) of primed cytotoxic CD8+ T
cells (CTLs). As tumor endothelial cells
express higher amounts of VEGF-R2 than nor-
mal vessels, CTLs selectively localize to tumor
vasculature and induce endothelial cell lysis. 
C: Vaccination against VEGF-R2 also results in
the generation of neutralizing antibodies to
VEGF-R2 that selectively blocks binding of
VEGF homodimers to VEGF-R2. This results in
impaired VEGF-R2 tyrosine kinase signaling
that is necessary for endothelial cell prolifera-
tion, survival, and migration, thereby block-
ing tumor angiogenesis.
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tions. However, the potential toxicities
that may be associated with immuno-
therapy targeted at angiogenic agents
should not dampen our enthusiasm for
moving these strategies through preclini-
cal studies, but rather should ignite the
desire to move forward quickly with a
watchful eye toward rationally designed
clinical trials.
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Nuclear factor of κB (NF-κB) defines a
family of related homo- and heterodimer-
ic transcription factors (Ghosh and Karin,
2002). It includes proteins that are syn-
thesized in their mature form and pro-
teins that are synthesized as large
precursors that undergo proteolytic pro-
cessing. The first group encompasses
RelA, RelB, and c-Rel, which have an N-
terminal Rel homology domain (RHD),
required for DNA binding and dimeriza-
tion, and a C-terminal region with trans-
activating properties (Figure 1). These
proteins are held in the cytoplasm by
“Inhibitors of κB” (IκB) proteins, charac-
terized by 6–7 ankyrin repeats that are
required for binding to the RHD of Rel
proteins and masking their nuclear local-
ization sequences. Upon cell stimulation,
the IκBs are phosphorylated and under-
go ubiquitin-dependent degradation. The
liberated NF-κB dimers enter the
nucleus and act as sequence-specific
transcription factors. The second group
consists of NF-κB1/p105 and NF-
κB2/p100 and their products p50 and
p52, respectively.The precursors contain
an N-terminal RHD as well as a C-termi-
nal region that contains ankyrin repeats
similar to those in IκBs (Figure 1). In their
C terminus, the precursors contain a
death domain (DD). By virtue of their
ankyrin repeats and their ability to dimer-
ize with other Rel proteins, p105 and
p100 act like IκBs (Mercurio et al., 1993).
While p105 processing is largely consti-
tutive, processing of p100 is triggered by
its phosphorylation and ubiquitination in
a manner akin to IκB degradation (Xiao
et al., 2001). Limited proteolysis results
in generation of the mature NF-κB2/p52
transcription factor consisting of the N-
terminal RHD.
The pathways that lead to activation
of NF-κB and processing of p100 depend
on components of the IκB kinase (IKK)
complex, which contains two catalytic
subunits, IKKα and IKKβ, and a regulato-
ry subunit IKKγ/NEMO (Rothwarf et al.,
1998). After activation by stimuli like the
proinflammatory cytokine TNFα or bacte-
rial products such as LPS, IKKβ phos-
phorylates the IκBs, leading to their
degradation and nuclear entry of NF-κB
dimers. This pathway, named the canoni-
cal NF-κB activation pathway, applies pri-
marily to NF-κB dimers composed of
RelA, c-Rel, and p50. An alternative NF-
κB signaling pathway involving IKKα
leading to p100 processing has recently
been described (Senftleben et al., 2001).
This pathway is triggered upon occupan-
cy of BAFF (B cell activating factor)
receptor (BAFF-R) and CD40 on B cells
and lymphotoxin β receptor (LTβR) on
stromal cells. Activation of this pathway
results in disappearance of p100 and
nuclear translocation of p52:RelB dimers
(Dejardin et al., 2002; Senftleben et al.,
2001; Xiao et al., 2001). Processing of
p100 depends on the catalytic activities
of IKKα and another kinase, NIK, which
probably acts upstream of IKKα
(Senftleben et al., 2001). The function of
this pathway is still not well defined, but it
is likely to be required for B cell matura-
tion and formation of secondary lymphoid
organs (Senftleben et al., 2001). The DD
of p100 is also involved in processing, as
its removal leads to constitutive process-
ing as well as inhibition of NIK-dependent
phosphorylation and processing (Fong et
al., 2002). Notably, mutant forms of NF-
κB2 were detected in B and T cell lym-
phomas, where they are caused by
chromosomal translocations that result in
truncations of the regulatory C-terminal
Is NF-κB2/p100 a direct activator of programmed cell death?
Transcription factor NF-κB has been implicated in cancer development due to its ability to upregulate expression of genes
with potentially prooncogenic functions, such as cell cycle regulators and antiapoptotic proteins (Karin et al., 2002). A recent
report by Wang et al. (2002) suggests that a structural motif, a death domain (DD), present in one of the mammalian NF-κB
proteins, NF-κB2/p100, allows it to directly activate cell death in a transcription-independent manner. Further, it is suggested
that loss of the proapoptotic function of NF-κB2/p100 is directly linked to its oncogenic activity in lymphomas.
